Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter
2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter
TipRanks 2 “Strong Buy” Penny Stocks That Could Go Growth Arguably the most controversial on
WARRINGTON, Pa., March 29, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and
Bloomberg Big Oil’s Secret World of Trading (Bloomberg Markets) — It was a bleak moment
Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau® Pro
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of
Benzinga If You Invested $1,000 In Bitcoin A single 12 months Ago, Here’s How Considerably
Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid
Bloomberg U.S. Companies Shell out Penalties to Refinance as Inflation Fears Loom (Bloomberg) — U.S.
– Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients